Trials / Completed
CompletedNCT00412880
BI 2536 Second Line Monotherapy in SCLC
An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 2536 | Intravenous Infusion |
Timeline
- Start date
- 2007-02-14
- Primary completion
- 2008-06-30
- Completion
- 2008-06-30
- First posted
- 2006-12-19
- Last updated
- 2022-06-22
- Results posted
- 2022-05-31
Locations
10 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00412880. Inclusion in this directory is not an endorsement.